CTLA4-Ig abrogates the anti-globulin response and prolongs cardiac allograft survival after anti-CD2 treatment

Transplant Immunology

Volumn 12, Issue 1, 2003, Pages 1-7

  Stell, David ^a   Marshall, Hilary ^a   Bradley, J Andrew ^a   Bolton, Eleanor M ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Anti CD2; Cardiac allograft survival; CTLA4 Ig; T cell depletion

Indexed keywords

CD2 ANTIGEN MONOCLONAL ANTIBODY; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX34; MONOCLONAL ANTIBODY OX55; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HEART DISEASE; HEART TRANSPLANTATION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RECIPIENT; T LYMPHOCYTE;

EID: 0142213315     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(03)00061-3     Document Type: Article

References (39)

1. Beyers AD, Barclay AN, Law DA, He Q, Williams AF. Activation of T lymphocytes via monoclonal antibodies against rat cell surface antigens with particular reference to CD2 antigen. Immunol Rev 1989;111:59.
2. Brown MH, Cantrell DA, Brattsand G, Crumpton MJ, Gullberg M. The CD2 antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface of human T lymphocytes. Nature 1989;339(6225):551.
3. Meuer SC, Hussey RE, Fabbi M, et al. An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 1984;36(4):897.
4. Bierer BE, Barbosa J, Herrmann S, Burakoff SJ. Interaction of CD2 with its ligand, LFA-3, in human T cell proliferation. J Immunol 1988;140(10):3358.
5. Moingeon P, Chang HC, Sayre PH, et al. The structural biology of CD2. Immunol Rev 1989;111:111.
6. Sehajpal PK, Sharma VK, Ingulli E, Stenzel KH, Suthanthiran M. Synergism between the CD3 antigen- and CD2 antigen-derived signals. Exploration at the level of induction of DNA-binding proteins and characterization of the inhibitory activity of cyclosporine. Transplantation 1993;55(5):1118.
7. van der Merwe PA, Barclay AN, Mason DW, et al. Human cell-adhesion molecule CD2 binds CD58 [LFA-3] with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry 1994;33(33):10149.
8. Nakamura T, Takahashi K, Fukazawa T, et al. Relative contribution of CD2 and LFA-1 to murine T and natural killer cell functions. J Immunol 1990;145(11):3628.
9. Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: Implications for T-cell function. Immunol Today 1996;17(4):177.
10. Ohno H, Nakamura T, Yagita H, Okumura K, Taniguchi M, Saito T. Induction of negative signal through CD2 during antigen-specific T cell activation. J Immunol 1991;147(7):2100.
11. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178(1):211.
12. Mentz F, Mossalayi MD, Ouaaz F, Debre P. Involvement of cAMP in CD3 T cell receptor complex- and CD2-mediated apoptosis of human thymocytes. Eur J Immunol 1995;25(6):1798.
13. Rouleau M, Mollereau B, Bernard A, et al. CD2 induced apoptosis of peripheral T cells. Transplant Proc 1997;29(5):2377.
14. Mollereau B, Deckert M, Deas O, et al. CD2-induced apoptosis in activated human peripheral T cells: A Fas-independent pathway that requires early protein tyrosine phosphorylation. J Immunol 1996;156(9):3184.
15. Dumont C, Deas O, Mollereau B, et al. Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb [BTI-322] in activated human peripheral T cells. J Immunol 1998;160(8):3797.
16. Bonnefoy-Berard N, Fournel S, Genestier L, Flacher M, Quemeneur L, Revillard JP. In vitro functional properties of antithymocyte globulins: Clues for new therapeutic applications? Transplant Proc 1999;30(8):4015.
17. Ida H, Anderson P. Activation-induced NK cell death triggered by CD2 stimulation. Eur J Immunol 1998;28(4):1292.
18. Bromberg JS, Chavin KD, Altevogt P, et al. Anti-CD2 monoclonal antibodies alter cell-mediated immunity in vivo. Transplantation 1991;51(1):219.
19. Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993;55(4):901.
20. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994;58(10):1082.
21. Bai Y, Fu S, Honig S, et al. CD2 is a dominant target for allogeneic responses. Am J Transplant 2002;2(7):618.
22. Woodward JE, Qin L, Chavin KD, et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: Inhibition of CD2 plus CD28 pathways. Transplantation 1996;62(7):1011.
23. Sido B, Otto G, Zimmermann R, Muller P, Meuer SC, Dengler TJ. Modulation of the CD2 receptor and not disruption of the CD2/CD48 interaction is the principal action of CD2-mediated immunosuppression in the rat. Cell Immunol 1997;182(1):57.
24. Sido B, Dengler TJ, Otto G, Zimmermann R, Muller P, Meuer SC. Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection vs. specific antibody production. Eur J Immunol 1998;28(4):1347.
25. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969;57(2):225.
26. Driscoll PC, Cyster JG, Campbell ID, Williams AF. Structure of domain 1 of rat T lymphocyte CD2 antigen [see comments]. Nature 1991;353(6346):762.
27. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173(3):721.
28. Jaques BC, Ahmiedat H, Alastair Gracie J, et al. Thymus-dependent, anti-CD4-induced tolerance to rat cardiac allografts. Transplantation 1998;66(10):1291.
29. Hunig T, Wallny HJ, Hartley JK, Lawetzky A, Tiefenthaler G. A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes. J Exp Med 1989;169(1):73.
30. O'Flynn K, Krensky AM, Beverley PC, Burakoff SJ, Linch DC. Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor. Nature 1985;313(6004):686.
31. Bohmig G, Kovarik J, Holter W, Pohanka E, Zlabinger G. Specific down regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. J Immunol 1994;152:3720.
32. Brown MH, Preston S, Barclay AN. A sensitive assay for detecting low-affinity interactions at the cell surface reveals no additional ligands for the adhesion pair rat CD2 and CD48. Eur J Immunol 1995;25(12):3222.
33. Seder RA, Germain RN, Linsley PS, Paul WE. CD28-mediated costimulation of interleukin 2 [IL-2] production plays a critical role in T cell priming for IL-4 and interferon gamma production. J Exp Med 1994;179(1):299.
34. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993;261(5121):609.
35. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig [see comments]. Science 1992;257(5071):789.
36. Ronchese F, Hausmann B, Hubele S, Lane P. Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo. J Exp Med 1994;179(3):809.
37. Schwarz M, Bohuslav J, Majdic O, Stockinger H, Knapp W, Holter W. Identification of the TS2/18-recognized epitope on the CD2 molecule as a target for suppression of T cell cytokine synthesis. J Immunol 1995;154(11):5813.
38. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995;3(1):87.
39. Noel PJ, Boise LH, Green JM, Thompson CB. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996;157(2):636.